The IMpower-132 trial for non small cell lung cancer

Bookmark and Share
Published: 29 Oct 2018
Views: 2338
Dr Vassiliki Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, US

Dr Vassiliki Papadimitrakopoulou speaks with ecancer at ESMO 2018 in Munich about her abstract for metastatic NSCLC regarding the IMpower-132 trial.

She gives a brief outline of the trial design and preliminary results, as well as information about subgroup analyses from the study.

These results are also discussed by Dr Fabrice Barlesi, here.

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

The abstract that I am involved with in metastatic non-small cell lung cancer that is being presented at this meeting is an analysis of subgroups from the IMpower132 clinical trial which is a randomised clinical trial comparing standard non-squamous chemotherapy, platinum pemetrexed, with platinum pemetrexed and the addition of atezolizumab. I reported these results at the World Lung Meeting this year, the primary analysis included progression free survival, investigator assessed, and the investigational regimen containing atezolizumab was superior to standard platinum chemotherapy. Overall survival analysis data were not mature, they were numerically superior for the investigational arm.

In this meeting Dr Fabrice Barlesi is reporting subgroup analyses from this trial with some interesting findings pertaining to benefit in patients of Asian origin, older patients and patients that are never smokers.